Glenmark's antiviral combination for moderate Covid-19 shows no benefit

The trial's findings confirm that the addition of umifenovir does not show any incremental benefit in clinical outcomes, the company said

India's Glenmark Pharmaceuticals Ltd said on Friday its clinical trial testing a combination of the antiviral drugs umifenovir and favipiravir in moderate hospitalized Covid-19 patients did not show any significant benefit.
 

The trial's findings confirm that the addition of umifenovir does not show any incremental benefit in clinical outcomes, Monika Tandon, senior vice president & head, Clinical Development, Global Specialty/Branded Portfolio at the company, said in a statement, adding that favipiravir alone remains the effective choice for mild to moderate Covid-19 infection.
 

Favipiravir is made under the brand name Avigan by Japan's Fujifilm Holdings Corp and was